The win ratio: a new approach to the analysis of composite endpoints in clinical trials based on clinical priorities by Wang, Duolao et al.
ORAL PRESENTATION Open Access
The win ratio: a new approach to the analysis of
composite endpoints in clinical trials based on
clinical priorities
Duolao Wang
*, Con Ariti, Tim Collier, Stuart Pocock
From Clinical Trials Methodology Conference 2011
Bristol, UK. 4-5 October 2011
Background
The conventional reporting of composite endpoints in
clinical trials is unsatisfactory in that it emphasises each
patient’s first event which is often of lesser clinical
importance. The objectives of this talk are to introduce
the concept of the win ratio for reporting composite
endpoints to address this problem and to assess the new
method by analysing real trials.
Methods and results
Patients in the new and control treatment are formed
into matched pairs based on their risk profiles. Con-
sider a primary composite endpoint, e.g. cardiovascular
(CV) death and heart failure hospitalisation (HF hosp)
in heart failure trials. For each matched pair the new
treatment patient is labelled a “winner” or a “loser” if
it is known who had a CV death first. If that is not
known, they are labelled a “winner” or “loser” if it is
known who had a HF hosp first. Otherwise they are
considered tied. The win ratio is the total number of
winners divided by the total numbers of losers. If for-
mation of matched pairs is impracticable then an alter-
native win ratio can be obtained by comparing all
possible unmatched pairs. This method is insightfully
illustrated by re-analyses of the EMPHASIS-HF,
PARTNER B and CHARM trials.
Conclusions
The win ratio is a powerful and easy to use method for
reporting composite endpoints, and gives appropriate
priority to the more clinically important event, e.g.
mortality. We encourage its use in future trial design
and analysis.
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